Skip to main content
SpringerLink
Log in
Book cover

Grundlagen der Neuro-Psychopharmakologie pp 137–213Cite as

Psychologische Grundlagen

  • Chapter

Zusammenfassung

Die Geschichte der kognitiven Psychopharmakologie ist eng verbunden mit Entwicklungen im Bereich der experimentellen Psychologie und akademischen Psychiatrie. Es war v. a. Emil Kraepelin (1856–1926), der mit seinen pharmakologischen Experimenten den Beginn der modernen Psychopharmakologie einleitete. Als wissenschaf licher Assistent arbeitete Kraepelin sehr eng mit Wilhelm Wundt (1832–1920) an der Universität Leipzig zusammen. Kraepelin widmete sich bereits in frühen Jahren seiner akademischen Ausbildung intensiv der experimentellen Psychologie und untersuchte Effekte psychoaktiver Substanzen auf Aufmerksamkeitsprozesse und komplexe kognitive Funktionen, wie Gedächtnis und Sprache. Eine Reihe der durch ihn eingeführten methodischen Innovationen, wie automatisierte Reaktionszeiterfassung, Placebokontrolle oder systematische Untersuchung von Dosierungsvarianten, stellten wichtige Grundlagen für die spätere psychopharmakologische Forschung dar.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alexopoulos GS, Kiosses DN, Klimstra S et al. (2002) Clinical presentation of the „depression-executivedysfunction-syndrome„ of late life. Am J Geriatr Psychiatry 10: 98–106

    PubMed  Google Scholar 

  • Amado-Boccara I, Gougoulis N, Poirier Littre MF et al. (1995) Effects of antidepressants on cognitive functions: a review. Neurosci Biobehav Rev 19: 479–493

    Article  CAS  PubMed  Google Scholar 

  • Barbee JG (1993) Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry 54 (suppl 10): 86–97, discussion 98–101

    PubMed  Google Scholar 

  • Barker MJ, Greenwood KM, Jackson M et al. (2004a) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18: 37–48

    Article  CAS  PubMed  Google Scholar 

  • Barker MJ, Greenwood KM, Jackson M et al. (2004b) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19: 437–454

    Article  PubMed  Google Scholar 

  • Bilder RM, Goldman RS, Robinson D et al. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry 157: 549–559

    Article  CAS  PubMed  Google Scholar 

  • Bilder RM, Goldman RS, Volavka J et al. (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018–1028

    Article  PubMed  Google Scholar 

  • Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews 1: CD005593

    Google Scholar 

  • Birks J, Flicker L (2003) Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 1: CD000442

    Google Scholar 

  • Birks J, Grimley EV, Van Dongen M (2002) Ginkgo biloba for cognitive impairment in dementia. Cochrane Database Syst Rev 4: CD003120

    Google Scholar 

  • Bogerts B (2002) Bedeutung des Frontalhirns für die Pathophysiologie schizophrener Erkrankungen. In: Förstl H (Hrsg) Frontalhirn. Funktionen und Erkrankungen, Springer, Berlin, S 181–205

    Google Scholar 

  • Bowie CR, Harvey PD (2006) Treatment of cognitive deficits in schizophrenia. Curr Opin Investig Drugs 7: 608–613

    CAS  PubMed  Google Scholar 

  • Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36: 717–725

    Article  CAS  PubMed  Google Scholar 

  • Buffet-Jerrot SE, Stewart SH, Bird S et al. (1998) An examination of differences in the time course of oxazepam’s effects on implicit vs. explicit memory. J Psychopharmacol 12: 338–347

    Article  Google Scholar 

  • Cassano GB, Puca F, Scappichio PL et al. (2002) Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 63: 396–402

    Article  CAS  PubMed  Google Scholar 

  • Correy-Bloom J, Anand R, Veach J (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acethylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65

    Google Scholar 

  • Cowley DS, Roy-Byrne PP, Radant A et al. (1995) Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 12: 147–157

    Article  CAS  PubMed  Google Scholar 

  • Cuesta MJ, Peralta V, Zarzuela A (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17–28

    Article  CAS  PubMed  Google Scholar 

  • Curran HV (1986) Tranquilising memories: a review of the ef ects of benzodiazepines on human memory. Biol Psychol 23: 179–213

    Article  CAS  PubMed  Google Scholar 

  • Curran HV, schiwy W, Lader M (1987) Differential amnestic effects of benzodiazepines: A dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacol 92: 358–364

    Article  CAS  Google Scholar 

  • Curran HV, Sakulsripong M, Lader M (1988) Antidepressants and human memory: An investigation of four drugs with different sedative and anticholinergic prof les. Psychopharmacol 95: 520–527

    Article  CAS  Google Scholar 

  • Doraiswamy PM, Krishnan KR, Oxman T et al. (2003) Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci 58: 1137–1144

    Article  Google Scholar 

  • Edwards JG (1995) Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants. CNS Drugs 4: 141–159

    Article  CAS  Google Scholar 

  • Fagerlund B, Mackeprang D, Gade A et al. (2004) Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first episode drug naive schizophrenic patients. CNS Spectr 9: 364–374

    Article  PubMed  Google Scholar 

  • Gladsjo JA, Rapaport MH, Mckinney R et al. (2001) Absence of neuropsychologic deffcits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol 21: 131–138

    Article  CAS  PubMed  Google Scholar 

  • Good KP, Kiss I, Buiteman C et al. (2002) Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 43: 45–49.

    Article  Google Scholar 

  • Goldberg TE, Gold JM (1995) Neurocognitive functioning in patients with schizophrenia. In: FE Bloom, DJ Kupfer Hrsg Psychopharmacology — The fourth generation of progress. Raven Press, New York, 1245–1257

    Google Scholar 

  • Goldberg TE, Greenberg RD, Griffin SJ et al. (1993) The ef ects of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43–48

    Article  CAS  PubMed  Google Scholar 

  • Grafmann J, Litvan I (1999) Importance if deficits in executive functions. Lancet 354: 1921–1923.

    Article  Google Scholar 

  • Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 151: 357–362

    Google Scholar 

  • Green MF (2002) Recent studies on the neurocognitive ef ects of second-generation antipsychotic medications. Curr Opin Psychiatry 15: 25–29

    Article  Google Scholar 

  • Green MF, Marshall BD Jr, Wirshing WC et al. (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799–804.

    Article  CAS  PubMed  Google Scholar 

  • Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 72: 41–51

    Article  PubMed  Google Scholar 

  • Hagger C, Buckley P, Kenny JT et al. (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712

    Article  CAS  PubMed  Google Scholar 

  • Hamilton SH, Edgell ET, Revicki DA et al. (2000) Functional outcomes in schizophrenia. A comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15: 245–255

    Article  CAS  PubMed  Google Scholar 

  • Harvey PD, Siu CO, Romano S (2004a) Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 172: 324–332

    Article  CAS  Google Scholar 

  • Harvey PD, Meltzer H, Simpson GM et al. (2004b) Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66: 101–113

    Article  PubMed  Google Scholar 

  • Hindmarch I (1995) The behavioural toxicity of the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 9: 13–17

    Article  PubMed  Google Scholar 

  • Hohwy J, Rosenberg R (2005) Cognitive neuropsychiatry: Conceptual, methodological and philosophical perspectives. World J Biol Psychiatry 6: 192–197

    Article  PubMed  Google Scholar 

  • Kandel ER (1998) A new intellectual framework for psychiatry. Am J Psychiatry 4: 457–469

    Article  Google Scholar 

  • Kasper S, Resinger E (2003) Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 28: 27–38

    Article  CAS  PubMed  Google Scholar 

  • Keefe RSE, Silva SG, Perkins DO, Liebermann J (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201–222

    Article  CAS  PubMed  Google Scholar 

  • Keefe RS, Seidmann LJ, Christensen BK et al. (2006) Long-term neurocognitive ef ects of olanzapine or lowdose haloperidol in first episode psychosis. Biol Psychiatry 59: 97–105

    Article  CAS  PubMed  Google Scholar 

  • Kern RS, Green MF, Marshall BD et al. (1998) Risperidone vs. Haloperidol on reaction time, manual dexterity, and motor learning in treatment resistant schizophrenia patients. Biol Psychiatry 44: 726–732

    Article  CAS  PubMed  Google Scholar 

  • Kern RS, Green MF, Cornblatt BA et al. (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187: 312–320

    Article  CAS  Google Scholar 

  • Kerr JS, Hindmarch I (1996) Citalopram and other antidepressants: Comparative effects on cognitive function and psychomotor performance. Journal of Serotonin Research 3: 123–129

    CAS  Google Scholar 

  • Kilic C, Curran HV, Noshirvani H et al. (1999) Long term effects of alprazolam on memory: a 3.5 year follow up of agoraphobia/panic patients. Psychol Med 29: 225–231

    Article  CAS  PubMed  Google Scholar 

  • Klotz U, Laux G (1996) Tranquillantien. Therapeutischer Einsatz und Pharmakologie. 2. Auf. Wiss Verlagsges Stuttgart

    Google Scholar 

  • Kunert HJ, Herpertz S, Dass H (2002) Frontale Dysfunktionen als ätiologische Faktoren bei der Borderline-und antisozialen Persönlichkeitsstörung?. In: Förstl H (Hrsg) Frontalhirn. Funktionen und Erkrankungen, Springer, Berlin, S 291–313

    Chapter  Google Scholar 

  • Lagnaoui R, Begaud B, Moore N et al. (2002) Benzodiazepine use and risk of dementia: a nested case-control sudy. J Clin Epidemiol 55: 314–318

    Article  PubMed  Google Scholar 

  • Lane RM, O’Hanlon JF (1999) Cognitive and psychomotor effects of antidepressants with emphasis on selective serotonin reuptake inhibitors and the depressed elderly patient. German Journal of Psychiatry 2: 1–42

    Google Scholar 

  • Lautenbacher S, Gauggel S (2004) Neuropsychologie psychischer Störungen. Springer, Berlin Heidelberg New York Toronto

    Book  Google Scholar 

  • Le Bars PL, Katz MM, Berman N et al. (1997) A placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia. JAMA 278: 1327–1332

    Article  PubMed  Google Scholar 

  • Lister RG, File SE (1984) The nature of lorazepam-induced amnesia. Psychopharmacol 83: 183–187

    Article  CAS  Google Scholar 

  • Marder SR (2006) The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci 8: 109–113

    PubMed  PubMed Central  Google Scholar 

  • Martin JB (2002) The integration of neurology, psychiatry, and neuroscience in the 21st century. Am J Psychiatry 159: 695–704

    Article  PubMed  Google Scholar 

  • McGurk SR, Lee MA, Jayathilake K et al. (2004) Cognitive effects of olanzapine treatment in schizophrenia. Med Gen Med 10: 27

    Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006). Memantine for dementia. Cochrane Database Syst Rev 19: CD003154

    Google Scholar 

  • Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive functioning in schizophrenia. Schiophr Bull 25: 233–255

    Article  CAS  Google Scholar 

  • Mishara AL, Goldberg TE (2004) A meta analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013–1022

    Article  CAS  PubMed  Google Scholar 

  • Mowia A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment?: a double blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27: 67–70

    Article  CAS  Google Scholar 

  • Möller HJ (2000) Are all antidepressants the same? J Clin Psychiatry 61: 24–28

    PubMed  Google Scholar 

  • Naber D, Lambert M, Krausz M et al. (2002) Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Aufl. Uni-Med, Bremen

    Google Scholar 

  • Paterniti S, Duffouil C, Alperovitch A (2002) Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 22: 285–293

    Article  CAS  PubMed  Google Scholar 

  • Petersen RC, Thomas RG, Grundmann M et al. (2005) Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388

    Article  CAS  PubMed  Google Scholar 

  • Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitiv dysfunction in schizophrenia. Clin Ther 27: S25–S37

    Article  CAS  PubMed  Google Scholar 

  • Posner MI, Petersen SE (1990) The attention system of the human brain. Annu Rev Neurosci 13: 25–42

    Article  CAS  PubMed  Google Scholar 

  • Potter GG, Kittinger JD, Wagner HR et al. (2004) Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 29: 2226–2271

    Article  Google Scholar 

  • Purdon SE, Jones BDW, Stip E et al. (2000) Neuropsychological change in early phase schizophrenia during 12 month of treatment with olanzapine, risperidone, or haloperidole. Arch Gen Psychiatr 57: 249–258

    Article  CAS  PubMed  Google Scholar 

  • Purdon SE, Malla A, Labelle A et al. (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137–149

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ramnani N, Behrens TE, Penny W et al. (2004) New approaches for exploring anatomical and functional connectivity in the human brain. Biol Psychiatry 56: 613–619

    Article  PubMed  Google Scholar 

  • Rocca P, Calvarese P, Fagiano F et al. (2005). Citalopram versus sertraline in late life nonmajor clinically significant depression: a 1-year follow-up clinical trial. J Clin Psychiatry 66: 360–369

    Article  CAS  PubMed  Google Scholar 

  • Rossi A, Manchini F, Stratta P et al. (1997) Risperidone, negative symptoms and cognitive deficits in schizophrenia: an open study. Acta Psychiatr Scand 95: 40–43

    Article  CAS  PubMed  Google Scholar 

  • Sax KW, Strakowski SM, Keck PE (1998) Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 33: 151–155

    Article  CAS  PubMed  Google Scholar 

  • Schneider F, Habel U, Bestman S (2002). Affektive Störungen. In: Förstl H (Hrsg) Frontalhirn. Funktionen und Erkrankungen, Springer, Berlin, S 207–240

    Google Scholar 

  • Shimamura AP (1995) Memory and frontal lobe functions. In: MS Gazzaniga (Ed) The cognitive Neurosciences, MIT Press, Cambridge, London, S 803–812

    Google Scholar 

  • Simpson SW, Baldwin RC, Burns A et al. (2001) Regional cerebral volume measurements in late-life depression: relationship to clinical correlates, neuropsychological impairment and response to treatment. Int J Geriatr Psychiatry 16: 469–476

    Article  CAS  PubMed  Google Scholar 

  • Squire LR (1992) Memory and the hippocampus: a synthesis from findings with rats, monkeys and humans. Psychol Rev 99: 195–232

    Article  CAS  PubMed  Google Scholar 

  • Squire LR (2004) Memory systems of the brain: a brief history and current perspective. Neurobiol Learn Mem 82: 171–177

    Article  PubMed  Google Scholar 

  • Stein RA, Strickland TL (1998) A review of the neuropsychological effects of commonly used prescription medications. Arch Clin Neuropsychol 13: 258–284

    Article  Google Scholar 

  • Stratta P, Donda P, Rossi A et al. (2005) Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. Hum Psychopharmacol 20: 401–408

    Article  CAS  PubMed  Google Scholar 

  • Tabet N, Birks J, Grimley Evans J (2000) Vitamin E for Alzheimer’s disease. Cochrane Database Syst Review 4: CD002854

    Google Scholar 

  • Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67 (supplement 9): 9–13

    CAS  PubMed  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC et al. (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276

    Article  CAS  PubMed  Google Scholar 

  • Velligan DI, Newcomer J, Pultz J et al. (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239–248

    Article  PubMed  Google Scholar 

  • Verdoux H, Lagnaoui R, Begaud B (2004) Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological data. Psychol Med 35: 307–315

    Article  Google Scholar 

  • Wagner M, Quednow BB, Westheide J et al. (2005) Cognitive improvement in schizophrenia does not require a serotoninergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30: 381–390

    Article  CAS  PubMed  Google Scholar 

  • Wiedemann G (2002). Angsterkrankungen. In: Förstl H (Hrsg) Frontalhirn. Funktionen und Erkrankungen, Springer, Berlin, S 141–272

    Google Scholar 

  • Winblad B, Poritis N (1999) Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int Geriat Psychiatry 14: 135–146

    Article  CAS  Google Scholar 

  • Zihl J, Grön G, Brunnauer A (1998) Cognitive deficits in schizophrenia and affective disorders: evidence for a final common pathway disorder. Acta Psychiatr Scand 97: 351–357

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Abi-Dargham A, Kegeles LS et al. (2004) Striatal amphetamineinduced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55: 1001–1006

    Article  CAS  PubMed  Google Scholar 

  • Alluander C, Mangano R, Zhang J et al. (2004 Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallelgroup comparison with paroxetine. Hum Psychopharmacol 19: 387–396

    Article  CAS  Google Scholar 

  • Bellino S, Zizza M, Rinaldi C et al. (2006) Combined treatment of major depression in patients with borderline personality disorder: A comparison with pharmacotherapy. Can J Psychiatry 51: 453–460

    Article  PubMed  Google Scholar 

  • Bergman A, Harvey P, Lees-Roitman S et al. (1998) Verbal learning and memory in schizotypal personality disorder. Schizophr Bull 24: 635–641

    Article  CAS  PubMed  Google Scholar 

  • Blomhoff S, Haug TT, Hellstrom K et al. (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179: 23–30

    Article  CAS  PubMed  Google Scholar 

  • Blum K, Braverman ER, Wu S et al. (1997) Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol Psychiatry 2: 239–246

    Article  CAS  PubMed  Google Scholar 

  • Bogenschutz MP, George Nurnberg H (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65: 104–109

    Article  CAS  PubMed  Google Scholar 

  • Brandes M, Bienvenu OJ (2006) Personality and anxiety disorders. Curr Psychiatry Rep 8: 263–269

    Article  PubMed  Google Scholar 

  • Bronisch T, Habermeyer V, Herpertz SC (2008) Persönlichkeitsstörungen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie und Psychotherapie, 3. Auf. Springer, Berlin Heidelberg New York, 1031–1093

    Google Scholar 

  • Buchsbaum MS, Nenadic I, Hazlett EA et al. (2002) Differential metabolic rates in prefrontal and temporal Brodmann areas in schizophrenia and schizotypal personality disorder. Schizophr Res 54: 141–150

    Article  PubMed  Google Scholar 

  • Canli T, Lesch KP (2007) Long story short: The serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10: 1103–1109

    Article  CAS  PubMed  Google Scholar 

  • Carver CS (2005) Impulse and constraint: Perspectives from personality psychology, convergence with theory in other areas, and potential for integration. Person Social Psychol Rev 9: 312–333

    Article  Google Scholar 

  • Charney DS (2003) Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand 108 (suppl 417): 38–50

    Article  Google Scholar 

  • Clark DM, Ehlers A, McManus F et al. (2003) Cognitive therapy versus fluoxetine in generalized social phobia: A randomized, placebo-controlled trial. J Consult Clin Psychol 71: 1058–1067

    Article  PubMed  Google Scholar 

  • Clark LA (2007) Assessment and diagnosis of personality disorders: Perennial issues and an empirical reconceptualization. Annu Rev Psychol 58: 227–257

    Article  PubMed  Google Scholar 

  • Cloninger CR (1987) A systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry 44: 579–588

    Article  Google Scholar 

  • Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975–990

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF (1993) Psychopharmacologic studies in patients with personality disorders: Review and perspective. J Personal Disord (suppl): 181–192

    Google Scholar 

  • Coccaro EF, Kavoussi RJ (1997) Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54: 1081–1088

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Siever LH (2005) Neurobiology. In: Oldham JM, Skodol AE, Bender DS (eds) Textbook of personality disorders. American Psychiatric Publishing, Washington London, 155–169

    Google Scholar 

  • Coccaro EF, Siever LJ, Klar HM et al (1989) Serotoninergic studies in affective and personality disorder: Correlates with suicidal and impulsive aggressive behaviour. Arch Gen Psychiatry 46: 587–599

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Gabriel S, Siever LJ (1990) Busprione challenge: Preliminary evidence for a role for 5-HT1A receptors in impulsive aggressive behaviour in humans. Psychopharmacol Bull 26: 393–405

    CAS  PubMed  Google Scholar 

  • Coccaro EF, Lawrence T, Trestman R et al. (1991) Growth hormone responses to intravenous clonidine challenge correlates with behavioural irritability in psychiatric patients and in healthy volunteers. Psychiatry Res 39: 129–139

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Kavoussi RJ, Hauger RL (1995) Physiologic responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Int Clin Psychopharmacol 10: 177–180

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Kavoussi RJ, Sheline YI et al. (1996) Impulsive aggression in personality disorder: Correlates with 3H-Paroxetine binding in the platelet. Arch Gen Psychiatry 53: 531–536

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Kavoussi RJ, Cooper TB et al. (1997a) Central serotonin and aggression: Inverse relationship with prolactin response to d-fenfluramine, but not with CSF 5-HIAA concentration in human subjects. Am J Psychiatry 154: 4730–1435

    Google Scholar 

  • Coccaro EF, Kavoussi RJ, Trestman RL et al. (1997b) Serotonin function in personality and mood disorder: Intercorrelations among central indices and aggressiveness. Psychiatry Res 73: 1–14

    Article  CAS  PubMed  Google Scholar 

  • Coccaro EF, Lee R, McCloskey M (2003) Norepinephrine function in personality disorder: Plasma free MHPG correlates inversely with life history of aggression. CNS Spectr 8: 731–736

    Article  PubMed  Google Scholar 

  • Coid J, Yang M, Tyrer P et al. (2006) Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry 188: 423–31

    Article  PubMed  Google Scholar 

  • Comings DE, Johnson JP, Gonzalez NS et al. (2000) Association between the adrenergic alpha 2A receptor gene (ADRA2A) and measures of irritability, hostility, impulsivity and memory in normal subjects. Psychiatr Genet 10: 39–42

    Article  CAS  PubMed  Google Scholar 

  • Cornelius JR, Soloff PH, Perel JM et al. (1993) Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 150: 1843–1848

    Article  CAS  PubMed  Google Scholar 

  • Cowdry RW, Gardner DL (1988) Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Arch Gen Psychiatry 45: 111–119

    Article  CAS  PubMed  Google Scholar 

  • Craig IW (2007) The importance of stress and genetic variation in human aggression. BioEssays 29: 227–236

    Article  CAS  PubMed  Google Scholar 

  • Cramer V, Torgersen S, Kringlen E (2006) Personality disorders and quality of life. A population study. Compr Psychiatry 47: 178–84

    Article  PubMed  Google Scholar 

  • de la Fuente JM, Lotstra F (1994) A trial of carbam azepine in borderline personality disorder. Eur Neuropsychopharmacol 4: 470–486

    Google Scholar 

  • Depue RA, Lenzenweger M (2001) A neurobehavioral dimensional model. In Livesley WJ (Ed.) Handbook of personality disorders: Theory, research and treatment. Ney York: Guilford Press 137–176

    Google Scholar 

  • Dracheva S, Patel N, Woo DA et al. (2008) Increased serotonin 2C receptor mRNA editing: A possible risk factor for suicide. Mol Psychiatry 13: 1001–1010

    Article  CAS  PubMed  Google Scholar 

  • Egan MF, Goldberg TE, Kolachana BS et al. (2001) Effect of COMT Val 108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98: 6917–6922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fineberg NA, Sharma P, Sivakumaran T et al. (2007) Does obsessive-compulsive personality disorder belong within the obsessive-compulsive spectrum? CNS Spectr 12: 467–482

    Article  PubMed  Google Scholar 

  • Frankenburg FR, Zanarini MC (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebocontrolled pilot study. J Clin Psychiatry 63: 442–446

    Article  CAS  PubMed  Google Scholar 

  • Frankenburg FR, Zanarini MC (2006) Personality disorders and medical comorbidity. Curr Opin Psychiatry 19: 428–431

    Article  PubMed  Google Scholar 

  • Frankle WG, Lombardo I, New AS et al. (2005) Brain serotonin transporters distribution in subjects with in impulsive aggression: A positron emission study with [11C]McN5652. Am J Psychiatry 162: 915–923

    Article  PubMed  Google Scholar 

  • Friedel RO (2004) Dopamine dysfunction in borderline personality disorder: A hypothesis. Neuropsychopharmacology 29: 1029–1039

    Article  CAS  PubMed  Google Scholar 

  • Gabbard GO (2005) Mind, brain, and personality disorders. Am J Psychiatry 162: 648–655

    Article  PubMed  Google Scholar 

  • Gabbard GO, Allison SE (2007) Histrionic personality disorder. In: Gabbard GO (ed) Treatments of psychiatric disorders, 4th ed. American Psychiatric Publishing, Washington, London, 823–833

    Google Scholar 

  • Goldberg SC, Schulz SC, Schulz PM et al. (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 43: 680–686

    Article  CAS  PubMed  Google Scholar 

  • Goodman M, Triebwasser J, Sweta Shah BA et al. (2007) Neuroimaging in personality disorders: Current concepts, findings, and implications. Psychiatr Annals 37: 100–108

    Google Scholar 

  • Grilo C, Sanislow C, Gunderson J et al. (2004) Two-year stability and change of schizotypal, borderline, avoid ant and obsessive-compulsive personality dis orders. J Consult Clin Psychol 72: 767–775

    Article  PubMed  PubMed Central  Google Scholar 

  • Grilo C, Skodol A, Gunderson J et al. (2005) Longitudinal diagnostic efficiency of DSM-IV criteria for obsessive-compulsive personality disorder: A 2-year prospective study. Acta Psychiatr Scand 44: 64–68

    Google Scholar 

  • Grilo CM, Sanislow CA, Skodol AE et al. (2007) Longitudinal diagnostic effeciency of DSM-IV criteria for borderline personality disorder: A 2-year prospective study. Can J Psychiatry 52: 357–362

    Article  PubMed  Google Scholar 

  • Grosjean B, Tsai GE (2007) NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci 32: 103–115

    PubMed  PubMed Central  Google Scholar 

  • Grossman R (2004) Pharmacotherapy of personality disorders. In: Magnavita JJ (ed) Handbook of personality disorders. Wiley, Hoboken, NJ, 331–355

    Google Scholar 

  • Gunderson JG, Daversa MT, Grilo CM et al. (2006) Predictors of 2-year outcome for patients with borderline personality disorder. Am J Psychiatry 163: 822–826

    Article  PubMed  Google Scholar 

  • Gunnar M, Quevedo K (2007) The Neurobiology of stress and development. Annu Rev Psychol 58: 145–173

    Article  PubMed  Google Scholar 

  • Habermeyer V, Habermeyer E (2006) Polypharmazie in der Behandlung von Persönlichkeits-und Verhaltensstörungen. In: Th. Messer, M. Schmaugb (Hrsg.) Polypharmazie in der Behandlung psychischer Erkrankun gen. Springer Verlag, Wien New York, 121–137

    Chapter  Google Scholar 

  • Hariri AR, Mattay VS, Tessitore A et al. (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297: 400–403

    Article  CAS  PubMed  Google Scholar 

  • Harvey PD, Reichenberg A, Romerio M et al. (2006) Dualtask information processing in schizotypal personality disorder: Evidence of impaired processing capacity. Neuropsychology 20: 453–460

    Article  PubMed  Google Scholar 

  • Hazlett EA, Buchsbaum MS, Mehmet Haznedar M et al. (2008) Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 101: 111–123

    Article  PubMed  PubMed Central  Google Scholar 

  • Heimberg RG (2003) Cognitive behavioral and psychotherapeutic strategies for social anxiety disorder. Annual Meeting of the Anxiety Disorders Association of America. March 27–30, Toronto

    Google Scholar 

  • Herpertz SC (2007) Neurobiologie und Borderline-Per sönlichkeitsstörung. Psychotherapie im Dialog 8: 342–346

    Article  Google Scholar 

  • Herpertz SC, Steinmeyer EM, Sass H (1994) Patterns of comorbidity among DSM-III-R and ICD-10 personality disorders as observed with a new inventory fort he assessment of personality disorders. Eur Arch Psychiatry Clin Neuroscience 244: 161–169

    Article  CAS  Google Scholar 

  • Herpertz SC, Dietrich TM, Wenning B et al. (2001) Evidence of abnormal amygdale functioning in borderline personality disorder: A functional MRI study. Biol Psychiatry 50: 292–298

    Article  CAS  PubMed  Google Scholar 

  • Herpertz SC, Zanarini M, Schulz CS et al. (2007) WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8: 212–44

    Article  PubMed  Google Scholar 

  • Herpertz SC, DGPPN-Expertenkomitee (2009) S2-Praxis-leitlinien in Psychiatire und Psychotherapie. Behandlungsleitlinie Persönlichkeitsstörungen. Steinkopff, Darmstadt

    Google Scholar 

  • Hettema JM, An SS, Neale MC et al. (2006) Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry 11: 752–762

    Article  CAS  PubMed  Google Scholar 

  • Hollander E, Allen A, Lopez RP et al. (2001) A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62: 199–203

    Article  CAS  PubMed  Google Scholar 

  • Hopwood CJ, Morey LC, Shea MT et al. (2007) Personality traits predict current and future functioning comparably for individuals with major depressive and personality disorders. J Nerv Ment Dis 195: 266–269

    Article  PubMed  Google Scholar 

  • Hymowitz P, Frances A, Jacobsberg LB et al. (1986) Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 27: 267–271

    Article  CAS  PubMed  Google Scholar 

  • Jacob CP, Strobel A, Hohenberger K et al. (2004) Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster C personality disorders. Am J Psychiatry 161: 569–572

    Article  PubMed  Google Scholar 

  • Joyce PR, Rogers GR, Miller AL et al. (2003) Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders. Psychiatry Res 119: 1–10

    Article  CAS  PubMed  Google Scholar 

  • Kaabi B, Gelernter J, Woods SW et al. (2006) Genome scan for loci predisposing to anxiety disorders using a novel multivariate approach: Strong evidence for a chromosome 4 risk locus. Am J Hum Genet 78: 543–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kapfhammer HP (2006) Pharmakotherapie bei Persönlichkeitsstörungen. In: Möller HJ (Hrsg) Therapie psychischer Erkrankungen. 3. Auf. Thieme, Stuttgart, 1071–1084

    Google Scholar 

  • Kapfhammer HP (2007) Psychiatrische und pharmakothe rapeutische Interventionen in der Borderline-Therapie. In: Damman G, Janssen PL (Hrsg) Psychotherapie der Borderline-Störungen. Lindauer Psychotherapiemodule. 2. Auf. Stuttgart, Thieme, 208-219

    Google Scholar 

  • Kapfhammer HP (2008a) Anpassungsstörung, akute und posttraumatische Belastungsstörung. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie und Psychotherapie. 3. Auflage. Springer, Berlin Heidelberg New York Tokyo, 659–722

    Google Scholar 

  • Kapfhammer HP (2008b) Dissoziative Störungen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie und Psychotherapie. 3. Auflage. Springer, Berlin Heidelberg New York Tokyo, 723–765

    Google Scholar 

  • Kapfhammer HP (2008c) Angststörungen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie und Psychotherapie. 3. Auflage. Springer, Berlin Heidelberg New York Tokyo, 567–631

    Google Scholar 

  • Kasper S, Stein DJ, Loft H et al. (2005) Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186: 222–226

    Article  PubMed  Google Scholar 

  • Katschnig H, Amering M, Stolk JM et al. (1995) Longterm follow-up after a drug trial for panic disorder. Br J Psychiatry 167: 487–494

    Article  CAS  PubMed  Google Scholar 

  • Keshavan M, Shad M, Soloff P et al. (2004) Ef cacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 71: 97–101

    Article  PubMed  Google Scholar 

  • Khan AA, Jacobson KC, Gardner CO et al. (2005) Personality and comorbidity of common psychiatric disorders. Br J Psychiatry 186: 190–196

    Article  PubMed  Google Scholar 

  • Kirrane RM, Mitropulou V, Nunn M et al. (2000) Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 22: 14–18

    Article  CAS  PubMed  Google Scholar 

  • Kirrane RM, Mitropoulou V, Nunn M et al. (2001) Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 48: 1–5

    Article  CAS  PubMed  Google Scholar 

  • Kobak KA, Griest JH, Jefferson JW et al. (2002) Fluoxetine in social phobia: A double blind, placebo-controlled pilot study. J Clin Psychopharmacol 22: 257–262

    Article  CAS  PubMed  Google Scholar 

  • Koenigsberg HW, Reynolds D, Goodman M et al. (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64: 628–634

    Article  CAS  PubMed  Google Scholar 

  • Koenigsberg HW, Siever LJ, Guo X et al. (2004) Emotion processing in borderline personality disorder: A functional MRI perspective. Neuropsychopharmacology 29: 84

    Google Scholar 

  • Koenigsberg HW, Buchsaum MS, Buchsbaum BR et al. (2005) Functional MRI of visuospatial working memory in schizotypal personality disorder: A region-of-interest analysis. Psychol Med 35: 1019–1030

    Article  PubMed  Google Scholar 

  • Kool S, Schoevers RA, de Maat S et al. (2005) Efficacy of pharmacotherapy in depressed patients with and without personality disorders: A systematic review and meta-analysis. J Affect Disord 88: 269–278

    Article  CAS  PubMed  Google Scholar 

  • Kronmüller KT, Mundt C (2006) Persönlichkeit, Persönlichkeitsstörungen und Depression. Nervenarzt 77: 863–878

    Article  PubMed  Google Scholar 

  • Krueger RF, Skodol AE, Livesley WJ et al. (2007) Synthesizing dimensional and categorical approaches to personality disorders: Refining the research angenda for DSM-V Axis II. Int J Methods Psychiatr Res 16: 65–73

    Article  Google Scholar 

  • Lader M, Stender K, Burger V et al. (2004) Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, flexed-dose study. Depress Anxiety 19: 241–248

    Article  CAS  PubMed  Google Scholar 

  • Laruelle M, Kegeles L, Zea-Pance Y et al. (2002) Amphetamine-induced dopamine release in patients with schizotypal personality disorders studies by SPECT and [123] IBZM. Neuroimage 16: 61

    Article  Google Scholar 

  • Lees-Roitman SE, Mitropoulou V, Keefe RSE et al. (2000) Visuospatial working memory in schizotypal personality disorder patients. Schizophr Res 41: 447–455

    Article  Google Scholar 

  • Leiberich PK, Nickel MK, Tritt K et al. (2008) Lamotrigine treatment of aggression in female borderline patients, Part II: A 18-month follow-up. J Psychopharmacol 22: 805–808

    Article  CAS  PubMed  Google Scholar 

  • Lenzenweger MF (1999) Stability and change in personality disorder features: Findings from a longitudinal study of personality disorders. Arch Gen Psychiatry 56: 1009–1015

    Article  CAS  PubMed  Google Scholar 

  • Lenzenweger MF (2006) The longitudinal study of personality disorders: History, design considerations, and initial findings. J Personal Disord 20: 645–670

    Article  Google Scholar 

  • Leonardo ED, Hen R (2006) Genetics of affective and anxiety disorders. Annu Rev Psychol 57: 117–137

    Article  CAS  PubMed  Google Scholar 

  • Lesch KP, Bengel D, Heils A et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527–1531

    Article  CAS  PubMed  Google Scholar 

  • Levitt JJ, McCarley RW, Dickey CC et al. (2002) MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naïve patients with schizotypal personality disorder. Am J Psychiatry 159: 1190–1197

    Article  PubMed  PubMed Central  Google Scholar 

  • Liebowitz MR, Stein MB, Tancer M et al. (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66–74

    Article  CAS  PubMed  Google Scholar 

  • Liebowitz MR, Gelenberg AJ, Munjack D (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62: 190–198

    Article  CAS  PubMed  Google Scholar 

  • Lis E, Greenfield B, Henry M et al. (2007) Neuroimaging and genetics of borderline personality disorder: A review. J Psychiatry Neurosci 32: 162–173

    PubMed  PubMed Central  Google Scholar 

  • Livesley WJ (2007) A framework for integrating dimensional and categorical classifications of personality disorder. J Personal Disord 21: 199–224

    Article  Google Scholar 

  • Loew TH, Nickel MK, Muehlbacher M et al. (2006) Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol 26: 61–66

    Article  PubMed  Google Scholar 

  • Loranger AW, Sartorius N, Andreoli A et al. (1994) The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse and Mental Health Administration international pilot study of personality disorders. Arch Gen Psychiatry 51: 215–224

    Article  CAS  PubMed  Google Scholar 

  • Maier W, Lichtermann D, Klingler T et al. (1992) Prevalences of personality disorders (DSM-III-R) in the community. J Personal Disord 6: 187–196

    Article  Google Scholar 

  • Marcin MS, Nemeroff CB (2003) The neurobiology of social anxiety disorder: The relevance of fear and anxiety. Acta Psychiatr Scand 108 (suppl 417): 51–64

    Article  Google Scholar 

  • Markovitz PJ, Wagner SC (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 31: 773–777

    CAS  PubMed  Google Scholar 

  • Markovitz PJ, Calabrese JR, Schulz SC et al. (1991) Fluoxetine treatment of boderline and schizotypal personality disorder. Am J Psychiatry 148: 1064–1067

    Article  CAS  PubMed  Google Scholar 

  • Mathew SJ, Coplan JD, Gorman JM (2001) Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 158: 1558–1567

    Article  CAS  PubMed  Google Scholar 

  • Mcclure MM, Barch DM, Romero MJ et al. (2007a) The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 61: 1157–1160

    Article  CAS  PubMed  Google Scholar 

  • Mcclure MM, Romero MJ, Bowie CR et al. (2007b) Visualspatial learning and memory in schizotypal personality disorder: Continued evidence for the importance of working memory in the schizophrenia spectrum. Arch Clin Neuropsychol 22: 109–116

    Article  PubMed  Google Scholar 

  • Mcgirr A, Paris J, Lesage A et al. (2007) Risk factors for suicide completion in borderline personality disorder: A case-control study of cluster B comorbidity and impulsive aggression. J Clin Psychiatry 68: 721–9

    Article  PubMed  Google Scholar 

  • Mcglashan T, Grilo C, Sanislow E et al. (2005) Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: Toward a hybrid model of axis II disorders. Am J Psychiatry 162: 883–889

    Article  PubMed  PubMed Central  Google Scholar 

  • Mcmain S, Pos AE (2007) Advances in psychotherapy of personality disorders: A research update. Curr Psychiatry Rep 9: 46–52

    Article  PubMed  Google Scholar 

  • Meloy JR (2007) Antisocial personality disorder. In: Gabbard GO (ed) Treatments of psychiatric disorders, 4th ed. American Psychiatric Publishing, Washington, London, 775–789

    Google Scholar 

  • Mercer D (2007) Medications in the treatment of borderline personality disorder 2006. Curr Psychiatry Reports 9: 53–62

    Article  Google Scholar 

  • Meyer-Lindenberg A, Buckholtz JW, Kolachana B et al. (2006) Neural mechanisms of genetic risk for impulsivity and violence in humans. PNAS 103: 6269–6274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miczek KA, Fish EW, De BOLD JF et al. (2002) aSocial and neural determinants of aggressive behaviour: Pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology 163: 434–458

    Article  CAS  PubMed  Google Scholar 

  • Miczek KA, De Almeida RMM, Kravitz EA et al. (2007) Neurobiology of escalated aggression and violence. J Neuroscience 27: 11803–11806

    Article  CAS  PubMed  Google Scholar 

  • Minzenberg MJ, XU K, Mitropoulou V et al. (2006a) Catechol-O-methyltransferase Val158Met genotype variation is associated with prefrontal-dependent task performance in schizotypal personality disorder patients and comparison groups. Psychiatr Genet 16: 117–124

    Article  PubMed  Google Scholar 

  • Minzenberg MJ, Grossman R, New AS et al. (2006b) Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology 31: 197–203

    CAS  PubMed  Google Scholar 

  • Mitropoulou V, Harvey PD, Maldari LA et al. (2002) Neuropsychological performance in schizotypal personality disorder: Evidence regarding diagnostic specificity. Biol Psychiatry 52: 1175–1182

    Article  PubMed  Google Scholar 

  • Mitropoulou V, Goodman M, Sevy S et al. (2004) Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophr Res 70: 27–31

    Article  PubMed  Google Scholar 

  • Mitropoulou V, Harvey PD, Zegarelli G et al. (2005) Neuropsychological performance in schizotypal personality disorder: Importance of working memory. Am J Psychiatry 162: 1896–1903

    Article  PubMed  Google Scholar 

  • Montgomery SA, Montgomery D (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord 4: 291–298

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA, Montgomery D (1983) The prevention of recurrent suicidal acts. Br J Clin Pharmacol 15 Suppl 2: 183–188

    Article  Google Scholar 

  • Montgomery SA, Nil R, Durr-Pal N et al. (2005) A 24-week randomized, double-blind, placebo-controlled study of excitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66: 1270–1278

    Article  CAS  PubMed  Google Scholar 

  • Moran P, S Tewart R, Brugha T et al. (2007) Personality disorder and cardiovascular disease: Results from a national household survey. J Clin Psychiatry 68: 69–74

    Article  PubMed  Google Scholar 

  • Mulder RT (2002) Personality pathology and treatment outcome in major depression: A review. Am J Psychiatry 159: 359–371

    Article  PubMed  Google Scholar 

  • Mulder RT, Joyce PR, Frampton CMA et al. (2006) Six months of treatment for depression: Outcome and predictors of course of illness. Am J Psychiatry 163: 95–100

    Article  PubMed  Google Scholar 

  • Muller JE, Koen L, Seedat S et al. (2005) Social anxiety disorder: Current treatment recommendations. CND Drugs 19: 377–391

    Article  CAS  Google Scholar 

  • Murphy DL, Lesch KP (2008) Targeting the murine serotonin transporter: Insights into human neurobiology. Nat Rev Neurosci 9: 85–96

    Article  CAS  PubMed  Google Scholar 

  • Nelson RJ, Trainor BC (2007) Neural mechanisms of aggression. Nature Rev Neurosci 8: 536–546

    Article  CAS  Google Scholar 

  • New AS, Gelernter J, Yovelly et al. (1998) Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: A preliminary study. Am J Med Gent 81: 13–17

    Article  CAS  Google Scholar 

  • New AS, Gelernter J, Goodman M et al. (2001) Suicide, impulsive aggression and the HTR1B genotype. Biol Psychiatry 50: 62–65

    Article  CAS  PubMed  Google Scholar 

  • New AS, Hazlett EA, Buchsbaum MS et al. (2002) Blunted prefrontal cortical 18F-fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry 59: 621–629

    Article  CAS  PubMed  Google Scholar 

  • New AS, Trestman RF, Mitropoulou V et al. (2004a) Low prolactin response to fenf uramine in impulsive aggression. J Psychiatr Res 38: 223–230

    Article  PubMed  Google Scholar 

  • New AS, Buchsbaum MS, Hazlett EA et al. (2004b) Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology 176: 451–458

    Article  CAS  PubMed  Google Scholar 

  • New AS, Hazlett EA, Buchsbaum MS et al. (2007) Amygdala-prefrontal disconnection in borderline personality disorder. Neuropsychopharmacology 32: 1629–1640

    Article  CAS  PubMed  Google Scholar 

  • Newton-Howes G, Tyrer P, Johnson T (2006) Personality disorder and the outcome of depression: Meta-analysis of published studies. Br J Psychiatry 188: 13–20

    Article  PubMed  Google Scholar 

  • Nickel MK, Loew TH (2008) Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry 23: 115–117

    Article  PubMed  Google Scholar 

  • Nickel MK, Nickel C, Mitterlehner FO et al. (2004) Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. J Clin Psychiatry 65: 1515–1519

    Article  CAS  PubMed  Google Scholar 

  • Nickel MK, Nickel C, Kaplan P et al. (2005) Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biol Psychiatry 57: 495–499

    Article  CAS  PubMed  Google Scholar 

  • Nickel MK, Loew TH, Pedrosa Gil F (2007) Aripiprazole in treatment of borderline patients, part II: A 18-month follow-up. Psychopharmacology 191: 1023–1026

    Article  CAS  PubMed  Google Scholar 

  • Nickel MK, Muehlbacher M, Nickel C et al. (2006) Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind placebo-controlled study. Am J Psychiatry 163: 833–838

    Article  PubMed  Google Scholar 

  • Nielson DA, Goldman D, Virkkunen M et al. (1994) Suicidality and 5-hydroxindoleacetic acid concentration associated with a tryptophan hydroxylase poly morphism. Arch Gen Psychiatry 51: 34–38

    Article  Google Scholar 

  • Nose M, Cipriani A, Biancosino B et al. (2006) Efficacy of pharmacotherapy against core traits of borderline personality disorder: A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21: 345–353

    Article  PubMed  Google Scholar 

  • Noyes R Jr, Moroz G, Davidson JR et al. (1997) Moclobemide in social phobia: A controlled dose-response trial. J Clin Psychopharmacol 17: 247–254

    Article  CAS  PubMed  Google Scholar 

  • Oldham JM, Skodol AE, Kellman D et al. (1992) Diagnosis of DSM-III-R personality disorders by two structured interviews: Patterns of comorbidity. Am J Psychiatry 149: 213–220

    Article  CAS  PubMed  Google Scholar 

  • Paris J (2003) Personality disorders overtime: Precursors, course, and outcome. Washington DC. American Psychiatric Press

    Google Scholar 

  • Paris J (2005) Neurobiological dimensional models of personality: A review of the models of Cloninger, Depue, and Siever. J Personal Disord 19: 156–170

    Article  Google Scholar 

  • Paris J (2007) The nature of borderline personality disorders: Multiple dimensions, multiple symptoms, but one category. Personal Disord 21: 457–473

    Article  Google Scholar 

  • Paris J, Zweig-Frank H (2001) A 27-year follow-up of patients with borderline personality disorder. Compr Psychiatry 42: 482–487

    Article  CAS  PubMed  Google Scholar 

  • Paris J, Zweig-Frank H, Kin NM et al. (2004) Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. Psychiatry Res 121: 239–252

    Article  PubMed  Google Scholar 

  • Perry JC (2007) Cluster C personality disorders. In: Gabbard GO (ed) Treatments of psychiatric disorders, 4th ed. American Psychiatric Publishing, Washington, London, 835–854

    Google Scholar 

  • Pezewas L, Meyer-Lindenberg A, Drabant EM et al. (2005) 5-HTTLPR polymorphism impacts human cingulateamygdala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 8: 828–834

    Article  CAS  Google Scholar 

  • Philipsen A, Richter H, Schmahl C et al. (2004) Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 65: 1414–1419

    Article  CAS  PubMed  Google Scholar 

  • Prasko J, Dockery C, Horacek J et al. (2006) Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 27: 473–481

    CAS  PubMed  Google Scholar 

  • Raine A, Lencz T, Yaralian P et al (2002) Prefrontal structural and functional deficits in schizotypal personality disorder. Schizophr Bull 28:501–513

    Article  PubMed  Google Scholar 

  • Rickels K, Mangano R, Khan A (2004) A double-blind, placebo-controlled of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacology 24: 488–496

    Article  CAS  Google Scholar 

  • Rinne T, Van den Brink W, Wouters L et al. (2002) SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159: 2048–2054

    Article  PubMed  Google Scholar 

  • Rocca P, Marchiaro L, Cocuzza E et al. (2002). Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 62: 241–244

    Article  Google Scholar 

  • Ronningstam EF, Maltsberger JT (2007) Narcissistic personality disorder. In: Gabbard GO (ed) Treatments of psychiatric disorders, 4th ed. American Psychiatric Publishing, Washington, London, 791–803

    Google Scholar 

  • Rybakowski JK, Drozdz W, Borkowska A (2007) Long-term administration of the low-dose risperidone in schizotaxia subjects. Hum Psychopharmacol 22: 407–412

    Article  CAS  PubMed  Google Scholar 

  • Salzmann C, Wolfson AN, Schatzberg A et al. (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacology 15: 23–29

    Article  Google Scholar 

  • Samuels J, Eaton WW, Bienvenu OJ et al. (2002) Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry 180: 536–542

    Article  PubMed  Google Scholar 

  • Schmahl C, Bremner JD (2006) Neuroimaging in borderline personality disorder. J Psychiatr Res 40: 419–427

    Article  PubMed  Google Scholar 

  • Schneier FR, Gortz D, Camperas R et al. (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172: 70–72

    Article  CAS  PubMed  Google Scholar 

  • Schulz SC, Camlin KL, Berry SA et al. (1999) Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 46: 1429–1435

    Article  CAS  PubMed  Google Scholar 

  • Schulz SC, Zanarini M, Bateman A (2008) Olanzapine for the treatment of borderline personality disorder: A flexible dose. 12 week, randomized, double blind, placebo controlled study. Br J Psychiatry 193: 485–492

    Article  PubMed  Google Scholar 

  • Serban G, Siegel S (1984) Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 141: 1455–1458

    Article  CAS  PubMed  Google Scholar 

  • Shihabuddin L, Buchsbaum MS, Hazlett EA et al. (2001) Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch Gen Psychiatry 58: 877–884

    Article  CAS  PubMed  Google Scholar 

  • Siegel BV, Trestman RL, O’Flaithbheartaigh SO et al. (1996) D-amphetamine challenge effects on Wisconsin Card Sort Test performance in schizotypal personality disorder. Schizophr Res 20: 29–32

    Article  PubMed  Google Scholar 

  • Siever LJ (2005) Endophenotypes in the personality disorders. Dialogues Clin Neurosci 7: 139–151

    PubMed  PubMed Central  Google Scholar 

  • Siever LJ, Davis KL (2004) The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. Am J Psychiatry 161: 398–413

    Article  PubMed  Google Scholar 

  • Siever LJ, Amin F, Coccaro EF et al. (1993) CSF homovanillic acid in schizotypal personality disorder. Am J Psychiatry 150: 149–151

    Article  CAS  PubMed  Google Scholar 

  • Siever LJ, New AS, Kirrane R et al. (1998) New biological research strategies for personality disorders. In: Silk KR (Ed.) Biology of personality disorders. Washington DC: American Psychiatric Press, 27–62

    Google Scholar 

  • Siever LJ, Buchsbaum MS, New AS et al. (1999) D-fenfluramine response in impulsive personality disorder assessed with [18F]flrodeoxyglucose positron emission tomography. Neuropsychopharmacology 20: 413–423

    Article  CAS  PubMed  Google Scholar 

  • Siever LJ, Koenigsberg HW, Harvey P et al. (2002) Cognitive and brain function in schizoypal personality disorder. Schizophr Res 54: 157–167

    Article  PubMed  Google Scholar 

  • Siever LJ, New AS, Goodman M et al. (2004) Behavioral, cognitive, and neuroimaging intermediate phenotypes in impulsive personality disorders. Biol Psychiatry 55: 192

    Article  CAS  Google Scholar 

  • Silbersweig D, Clarkin JF, Goldstein M et al. (2007) Failure of frontolimbic inhibitory function in the context of negative emotion in borderline personality disorder. Am J Psychiatry 164: 1832–1841

    Article  PubMed  Google Scholar 

  • Simpson EB, Yen S, Costello E et al. (2004) Combined dialectical behavior therapy and f uoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65: 379–385

    Article  CAS  PubMed  Google Scholar 

  • Soler J, Pascual JC, Campins J et al (2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162: 1221–1224

    Article  PubMed  Google Scholar 

  • Soloff PH (1986) Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 43: 691–697

    Article  CAS  PubMed  Google Scholar 

  • Soloff PH (1998) Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62: 195–214

    CAS  PubMed  Google Scholar 

  • Soloff PH, George A, Nathan S et al. (1989) Amitripty-line versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 9: 238–246

    Article  CAS  PubMed  Google Scholar 

  • Soloff PH, Cornelius J, George A et al. (1993) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50: 377–385

    Article  CAS  PubMed  Google Scholar 

  • Soloff PH, Meltzer CC, Greer PJ et al. (2000) A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 47: 540–547

    Article  CAS  PubMed  Google Scholar 

  • Stein MB, Liebowitz MR, Lydiard RB et al. (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA 280: 708–713

    Article  CAS  PubMed  Google Scholar 

  • Stein MB, Fyer AJ, Davidson JR et al. (1999) Fluoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am J Psychiatry 156: 756–760

    CAS  PubMed  Google Scholar 

  • Stein DJ, Versiani M, Hair T et al. (2002) Efficacy of paroxetine for relapse prevention in social anxiety disorder. Arch Gen Psychiatry 59: 1111–1118

    Article  CAS  PubMed  Google Scholar 

  • Stein MB, Fallin MD, Schork NJ et al. (2005) COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology 30: 2092–2102

    Article  CAS  PubMed  Google Scholar 

  • Stein MB, Pollack MH, Bystritsky A et al. (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology 177: 280–288

    Article  CAS  PubMed  Google Scholar 

  • Stone MH (2007) Cluster A personality disorders: Paranoid, schizoid, and schizotypal. In: Gabbard GO (ed) Treatments of psychiatric disorders, 4th ed. American Psychiatric Publishing, Washington, London, 763–773

    Google Scholar 

  • Tebartz Von Elst L, Ludaescher P, Thiel T et al. (2007) Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder. Neurosci Lett 417: 36–41

    Article  CAS  Google Scholar 

  • Torgersen S, Kringlen E, Cramer V (2001) The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 58: 590–596

    Article  CAS  PubMed  Google Scholar 

  • Tritt K, Nickel C, Lahmann C et al. (2005) Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. J Psychopharmacol 19: 287–291

    Article  CAS  PubMed  Google Scholar 

  • Tyrer P, Gunderson J, Lyons M et al. (1997) Extent of comorbidity between mental state and personality disorders. J Personal Disord 11: 242–259

    Article  CAS  Google Scholar 

  • Tyrer P, Mulder R (2006) Management of complex and severe personality disorders in community mental health services. Curr Opin Psychiatry 19: 400–404

    Article  PubMed  Google Scholar 

  • Tyrer P, Coombs N, Ibrahimi F et al. (2007) Critical developments in the assessment of personality disorder. Br J Psychiatry 190: 51–59

    Article  Google Scholar 

  • Van Ameringen MA, Lane RM, WalÖker JR et al. (2001) Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158: 275

    Article  PubMed  Google Scholar 

  • Van Vliet IM, Den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine. Psychopharmacology 115: 128–134

    Article  PubMed  Google Scholar 

  • Verheul R, Herbrink M (2007) The efficacy of various modalities of psychotherapy for personality disorders: A systematic review of the evidence and clinical recommendations. Int Rev Psychiatry 19: 25–38

    Article  PubMed  Google Scholar 

  • Volavka J (1999) The neurobiology of violence: An update. J Neuropsychiatry Clin Neurosci 11: 307–314

    Article  CAS  PubMed  Google Scholar 

  • Westen D, Shedler J, Bradley R (2006) A prototype approach to personality disorder diagnosis. Am J Psychiatry 163: 846–856

    Article  PubMed  Google Scholar 

  • Whittle S, Allen NB, Lubman DI et al. (2006) The neurobiological basis of temperament: Towards a better understanding of psychopathology. Neurosci Biobehav Rev 30: 511–525

    Article  PubMed  Google Scholar 

  • Widiger TA (2007a) Current controversies in nosology and diagnosis of personality disorders. Psychiatr Ann 32: 93–99

    Google Scholar 

  • Widiger TA (2007b) Dimensional models of personality disorder. World Psychiatry 6: 79–83

    PubMed  PubMed Central  Google Scholar 

  • Zanarini MC, Frankenburg FR (2003) Omega-3-fatty acid treatment of women with borderline personality disorder: A double-blind placebo-controlled pilot study. Am J Psychiatry 160: 167–169

    Article  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR, Khera GS et al. (2001) Treatment histories of borderline inpatients. Compr Psychiatry 42: 144–150

    Article  CAS  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR, Hennen J et al. (2004a) Comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 161: 2108–2114

    Article  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65: 903–907

    Article  CAS  PubMed  Google Scholar 

  • Zanarini MC, Frankenburg FR, Hennen J et al. (2006) Prediction of the 10-years course of borderline personality disorder. Am J Psychiatry 163: 827–832

    Article  PubMed  Google Scholar 

  • Zimmerman M, Coryell W (1989) DSM-III personality disorder diagnoses in a nonpatient sample: Demographic correlates and comorbidity. Arch Gen Psychiatry 46: 682–689

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman M, Rothschild L, Chelminski I (2005) The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 162: 1911–1918

    Article  PubMed  Google Scholar 

Literatur

  • Arbeitsgruppe „Psychoedukation bei schizophrenen Erkrankungen“ (2008) Konsensuspapier zu psychoedukativen Interventionen bei schizophrenen Erkrankungen In: Bäuml J, Pitschel-Walz G. (Hrsg.) Psychoedukation bei schizophrenen Erkrankungen. Stuttgart: Schattauer 1–33

    Google Scholar 

  • Bäuml J, Pitschel-Walz G (Hrsg.) (2008) Psychoedukation bei schizophrenen Erkrankungen. Stuttgart: Schattauer

    Google Scholar 

  • Jensen M, Sadre Chirazi-Stark FM (2008) In: Bäuml J, Pitschel-Walz G (Hrsg.) Psychoedukation bei schizophrenen Erkrankungen. Stuttgart: Schattauer 163–175

    Google Scholar 

  • Kissling W (2001) Who is interested in the quality of everyday psychiatric care? International Clinical Psychopharmacology, 16 (suppl 3): S1–S4

    Article  PubMed  Google Scholar 

  • Kissling W, Rummel-Kluge C, Pitschel-Walz G (2003) Psychoedukation für Patienten mit schizophrenen Psychosen und deren Angehörige — Einführungsmanual für das Behandlungsteam. Alliance-Psychoedukations-Programm. Pf zer. Eigenverlag

    Google Scholar 

  • Pitschel-Walz G, Leucht S, Bäuml J et al. (2001) The effect of family interventions on relapse and rehospitalization in schizophrenia — a meta-analysis. Schizophr Bull 27: 73–92

    Article  CAS  PubMed  Google Scholar 

  • Pitschel-Walz G, Bäuml J, Bender W et al. (2006) Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich PIP-study. J Clin Psychiatry 67: 443–452.

    Article  PubMed  Google Scholar 

  • Rummel C, Hansen WP, Helbig A et al. (2005) Peer-topeer psychoeducation in schizophrenia: a new approach. J Clin Psychiatry 66: 1580–1585

    Article  PubMed  Google Scholar 

  • Rummel-Kluge C, Pitschel-Walz G, Bäuml J, Kissling W. (2006) Psychoeducation in schizophrenia: results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. Schizophrenia Bulletin 32: 765–775

    Article  PubMed  PubMed Central  Google Scholar 

  • Rummel-Kluge C, Pitschel-Walz G, Kissling W (2007) A fast implementable psychoeducation program for schizophrenia. Psychiatr Serv 58: 1226

    Article  PubMed  Google Scholar 

  • Rummel-Kluge C, Kissling W (2008) Psychoeducation for patients with schizophrenia and their families. Expert Rev Neurother 8: 1067–1077

    Article  PubMed  Google Scholar 

  • Wiedemann G (2008) Forschungsüberblick und Forschungsfragen zur Evidenzbasierung In: Bäuml J, Pitschel-Walz G (Hrsg.) Psychoedukation bei schizophrenen Erkrankungen. Stuttgart: Schattauer, 285–292

    Google Scholar 

  • Wienberg G, Schünemann-Wurmthaler S, Sibum B (2002) Schizophrenie zum Thema machen. PEGASUS Manual mit Materialien. Bonn: Psychiatrie Verlag

    Google Scholar 

Literatur

  • Bäuml J, Pitschel-Walz G (2008) Psychoedukation bei schizophrenen Erkrankungen. Konsensusbuch, Schattauer Verlag

    Google Scholar 

  • Bäuml J, Pitschel-Walz G (2007) Selbsthilfegruppen in der Rehabilitation. In: Becker T, Bäuml J, Pitschel-Walz G, Weig W (Hrsg) Rehabilitation bei schizophrenen Erkrankungen. Deutscher Ärzteverlag, Köln, S 261–270

    Google Scholar 

  • Bäuml J, Pitschel-Walz G, Volz A, Engel RR, Kissling W (2007) Psychoeducation in Schizophrenia: Impact on Rehospitalisation and Hospital Days — 7 Year Follow-Up of the Munich PIP-Study. J Clin Psychiatry 68: 854–861

    Article  PubMed  Google Scholar 

  • Beck, AT, Baruch E, JM Balter, Steer RA, Warman DM (2004) A new instrument for measuring insights: The Beck Cognitive Insight Scale. Schizophr Res 68: 319–329

    Article  PubMed  Google Scholar 

  • Berghaus G, Käferstein H, Rothschild NA (2006) Arzneimittel und Sicherheit. Dtsch Ärztebl 103: 1812–1816

    Google Scholar 

  • Bolsinger M (1999) Dogmatik der Arzthaftung. Nomos Verlag, Baden-Baden

    Google Scholar 

  • Brockhaus FA (1967) Aufklärung. Band II. Brockhaus-Verlag, Wiesbaden, S 60–62

    Google Scholar 

  • Dunn LB, Jeste DV (2003) Problem Areas in the Understanding of Informed Consent for Research: Study of Middle-Aged and Older Patients with Psychotic Disorders. Psychopharmacology 171: 81–85

    Article  CAS  PubMed  Google Scholar 

  • Franke W (2005) Sozialmedizinische Leistungsbeur teilung und ICF — Bedeutung für die Rehabilitations-Psychopharmakologie. In: Linden M, Müller WE (Hrsg) Rehabilitations-Psychopharmakotherapie. Deut scher Ärzteverlag, Köln, S 131–140

    Google Scholar 

  • Hornung WP, Holle R, Schulze-Mönking H. Klingberg S, Buchkremer G (1995) Psychoedukativ-Psychotherapeutische Behandlung von schizophrenen Patienten und ihren Bezugspersonen. Ergebnisse einer Einjahreskatamnese. Der Nervenarzt 66: 828–834

    CAS  PubMed  Google Scholar 

  • Helmchen H (1986) Aufklärung. In: Müller C (Hrsg) Lexikon der Psychiatrie, 2. Auflage, Springer Verlag, Heidelberg

    Google Scholar 

  • Hausner H, Cording C, Hajak G, Spiessl H (2008) Aufklärung und Einwilligung in Psychiatrie und Psychotherapie. Psychiat Prax 35: 163–169

    Article  Google Scholar 

  • Hamann J, Cohen R, Leucht S, Busch R, Kissling W (2005) Do Patients with Schizophrenia wish to be involved in Decisions about their Medical Treatment? Am J Psychiatry 162: 2382–2384

    Article  PubMed  Google Scholar 

  • Kissling W (1991) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer Verlag, Berlin

    Book  Google Scholar 

  • Laux G. Brunnauer A (2005) Beeinträchtigung der Fahr tüchtigkeit und beruflichen Leistungsfähigkeit durch Psychopharmaka unter Langzeitgesichtspunk ten. In: Linden M, Müller WE, Rehabilitations-Psychopharmakologie. Arzneimittelbehandlung chro nifizierender und chronofizierter psychischer Syndrome. Deutscher Ärzte-Verlag, Köln, S 141–154

    Google Scholar 

  • Laum H (2000) Wahrheit und Schweigen am Krankenbett. Zentralbl Schir 125: 920–925

    Article  CAS  Google Scholar 

  • Luderer HJ (2008) Rechtsfragen. In: Bäuml J, Pitschel-Walz G (Hrsg) Psychoedukation bei schizophrenen Erkrankungen, Schattauer Verlag, Stuttgart, S 315–328

    Google Scholar 

  • Marková IS, KH Roberts, Gallagher C, Boos H, McKenna PJ, Derrios GE (2003) Assessment of Insight in Psychosis: A re-standardisation of a new scale. Psychiatry Research 119: 81–88

    Article  PubMed  Google Scholar 

  • Müller WE (Hrsg) (2005) Rehabilitations-Psychopharmakotherapie. Deutscher Ärzteverlag, Köln, S 141–154

    Google Scholar 

  • Parzeller M, Wenk M, Zedler B, Rothschild M (2007) Aufklärung und Einwilligung bei ärztlichen Eingriffen. Dtsch Ärztebl 104: 507–515

    Google Scholar 

  • Pitschel-Walz G, Boerner R, Mayer C, Engel RR, Peuker I, Welschehold M, Bender W, BÄuml J, Buttner P, Kissling W (1995) Informationszentrierte Gruppen für schizophrene Patienten und deren Angehörige: Einfluss auf Wissen, Krankheitskonzept und Expressed Emotions (PIP-Studie). In: Bender W, Hubmann W, Moor F (Hrsg) Neuere Entwicklungen in der Behandlung schizophrener Psychosen. VTS-Verlag, München, S 295–309

    Google Scholar 

  • Pitschel-Walz G, Bäuml J (2007) Psychoedukation. In: Becker T, Bäuml J, Pitschel-Walz G, Weig W (Hrsg) Rehabilitation bei schizophrenen Erkrankungen. Deutscher Ärzteverlag, Köln, S 111–126

    Google Scholar 

  • Reichhardt T, Kissling W, Scheuring E, Hamann J (2008) Patientenbeteiligung in der Psychiatrie — eine kritische Bestandsaufnahme. Psychiat Prax 35: 111–121

    Article  Google Scholar 

  • Stieglitz RD, Vauth R (2005) Compliance und Patientenbeteiligung in der Rehabilitationspharma kotherapie. In: Linden M, Müller WE (Hrsg) Rehabilitations-Psychopharmakotherapie. Deutscher Ärzteverlag, Köln, S B 71–92

    Google Scholar 

  • Vitt KD, Erben CM, Reimann M, Rüther W (2008) Nachhaltige Information für Patienten. Dtsch Ärztebl 105: 1438–1439

    Google Scholar 

  • Vollmann J (2000) Aufklärung und Einwilligung in der Psychiatrie. Steinkopf-Verlag, Darmstadt

    Google Scholar 

  • Weih M, Thürauf N, Bleich S, Kornhuber J (2008) Of-Label-Use in der Psychiatrie. Fortschr Neurol Psychiatr 76: 7–13

    Article  CAS  PubMed  Google Scholar 

  • Wetterling T, Tessmann G, Junghans K (2002) Aufklärung über Medikamente. Psychiat Prax 29: 235–239

    Article  Google Scholar 

Literatur

  • Asani F, Eissmann I (2006) Medikamententraining Psych Pflege 12: 205–207

    Article  Google Scholar 

  • Braddock CH, III, Edwards KA, Hasenberg NM, Laidley TL, Levinson W (1999) Informed decision making in outpatient practice: time to get back to basics. JAMA 282: 2313–2320

    Article  PubMed  Google Scholar 

  • Bramesfeld A, Wedegartner F, Elgeti H, Bisson S (2007) How does mental health care perform in respect to service users’ expectations? Evaluating inpatient and outpatient care in Germany with the WHO responsiveness concept. BMC. Health Serv Res 7: 99–110

    Article  PubMed  PubMed Central  Google Scholar 

  • Charles C, Gafni A, Whelan T (1997) Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 44: 681–692

    Article  CAS  PubMed  Google Scholar 

  • Deber RB, Kraetschmer N, Irvine J (1996) What role do patients wish to play in treatment decision making? Arch Intern Med 156: 1414–1420

    Article  CAS  PubMed  Google Scholar 

  • DGPPN (2006) S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 Behandlungsleitlinie Schizophrenie. Steinkopf, Darmstadt

    Google Scholar 

  • DGPPN (2005) Rahmenkonzept Integrierte Versorgung Depression. Nervenarzt 76: 104–121

    Google Scholar 

  • Dierks M, Seidel G, Horch K, Schwartz F (2006) Gesundheitsberichterstattung des Bundes: Bürger-und Patientenorientierung im Gesundheitswesen. Robert Koch-Institut, Berlin

    Google Scholar 

  • Emanuel EJ, Emanuel LL (1992) Four models of the physician-patient relationship. JAMA 267: 2221–2226

    Article  CAS  PubMed  Google Scholar 

  • Ernst J, Holze S, Sonnenfeld C, Götze H, Schwarz R (2007) Medizinische Entscheidungsfindung im Krankenhaus-Ergebnisse einer explorativen Studie zum Stellenwert des shared decision making aus Sicht der Ärzte. Gesundheitswesen 69: 206–215

    Article  CAS  PubMed  Google Scholar 

  • Fleischmann H (2003) Was erwarten psychisch Kranke von der Behandlung im psychiatrischen Krankenhaus? Psychiat Prax 30 Suppl 2: S 136–S139

    Google Scholar 

  • Hamann J, Cohen R, Leucht S, Busch R, Kissling W (2005) Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry 162: 2382–2384

    Article  PubMed  Google Scholar 

  • Hamann J, Loh A, Kasper J, Neuner B, Spies C, Kissling W, Harter M, Heesen C (2006) Partizipative Entscheidungsfindung. Implikationen des Modells des „Shared Decision Making“ für Psychiatrie und Neurologie. Nervenarzt 77: 1071–1078

    Article  CAS  PubMed  Google Scholar 

  • Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, Kissling W (2006) Shared decision making for inpatients with schizophrenia. Acta Psychiatr Scand 114: 265–273

    Article  CAS  PubMed  Google Scholar 

  • Hamann J, Neuner B, Kasper J, Vodermaier A, Loh A, Deinzer A, Heesen C, Kissling W, Busch R, Schmieder R, Spies C, Caspari C, Harter M (2007) Participation preferences of patients with acute and chronic conditions. Health Expect 10: 358–363

    Article  PubMed  PubMed Central  Google Scholar 

  • Hamann J, Cohen R, Leucht S, Busch R, Kissling W (2007) Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 68: 992–997

    Article  PubMed  Google Scholar 

  • Hamann J, Mendel RT, Fink B, Pfeiffer H, Cohen R, Kissling W (2008) Patients’ and psychiatrists’ perceptions of clinical decisions during schizophrenia treatment. J Nerv Ment Dis 196: 329–332

    Article  PubMed  Google Scholar 

  • Hildebrandt H. (2001) Die Evaluation integrierter Versorgung und ihr wirtschaftliches Umfeld. In: Preuss et al. (Hrsg.) Managed Care — Evaluation und Performance-Measurement integrierter Versorgungsmodelle — Stand der Entwicklung in der EU, der Schweiz und den USA, Schattauer GmbH, Stuttgart

    Google Scholar 

  • Horch K, Wirz J (2005) Nutzung von Gesundheitsinformationen. Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz 48: 1250–1255

    CAS  Google Scholar 

  • Kahlert A (2006) Bedürfnisse von Patienten mit einer bipolaren Erkrankung während des stationären Aufenthalts. Psychiat Prax 33 Suppl 1: S7–11

    Article  Google Scholar 

  • Kiesler DJ, Auerbach SM (2006) Optimal matches of patient preferences for information, decision-making and interpersonal behavior: evidence, models and interventions Patient Educ Couns 61: 319–341

    Article  PubMed  Google Scholar 

  • Kilian R, Lindenbach I, Lobig U, Uhle M, Petscheleit A, Angermeyer MC (2003) Indicators of empowerment and disempowerment in the subjective evaluation of the psychiatric treatment process by persons with severe and persistent mental illness: a qualitative and quantitative analysis. Soc Sci Med 57: 1127–1142

    Article  PubMed  Google Scholar 

  • Kissling W, Seemann U, Fritze P (2004) Integrierte Versorgung. Neurotransmitter 10: 28–35

    Google Scholar 

  • Kissling W (2006) Integrierte Versorgung in der Psychiatrie. Neurotransmitter 12: 26–31

    Google Scholar 

  • Kissling W, Vogel C (2007) Erfahrungen mit dem „Münchner Modell“ — Integrierte Versorgung — eine Zwischenbilanz. Neurotransmitter 2.2007 11–19

    Google Scholar 

  • Klemperer D, Rosenwirth M (2005) Shared decision making: Konzept, Voraussetzungen und politische Implikationen. Bertelsmann Stiftung, Bremen

    Google Scholar 

  • Légaré F, Ratté S, Stacey D, Kryworuchko J, Gravel K, Turcot L, Graham I (2007) Interventions for improving the adoption of shared decision making by healthcare professionals (Protocol). The Cochrane Library 3: 1–10

    Google Scholar 

  • Loh A, Kremer N, Giersdorf N, Jahn H, Hanselmann S, Bermejo I, Harter M (2004) Informations-und Partizipationsinteressen depressiver Patienten bei der medizinischen Entscheidungsfindung in der hausärztlichen Versorgung. Z Arztl Fortbild Qualitätssich 98: 101–107

    PubMed  Google Scholar 

  • Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M (2007) The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Coun 67: 324–332

    Article  Google Scholar 

  • Meissner A (2006) Leserbrief Psychiat Prax 33: 251–252

    Article  Google Scholar 

  • Peinhaupt C, Nowak P (2005) PatientInnenbeteiligung und Integration im Gesundheitswesen. Empfehlungen des Wiener Modellprojekts PIK. Österreichische Krankenhauszeitung 46: 18–19

    Google Scholar 

  • Pitschel-Walz G, Bäuml J, Bender W, Engel RR, Wagner M, Kissling W (2006) Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich PIP-study. J Clin Psychiatry 67: 443–452.

    Article  PubMed  Google Scholar 

  • Post EP, Cruz M, Harman J (2006) Incentive Payments for Attendance at Appointments for Depression Among Low-Income African Americans. Psychiatr Serv 57: 414–6

    Article  PubMed  Google Scholar 

  • Reichhart T, Kissling W, Scheuring E, Hamann J (2008) Patientenbeteiligung in der Psychiatrie — eine kritische Bestandsaufnahme. Psychiat Prax 35: 111–121

    Article  Google Scholar 

  • Scheibler F, Stoffel MP, Barth C, Kuch C, Steffen P, Baldamus CA, Pfaff H (2005) [Shared decision-making as a new quality indicator in nephrology: a nationwide survey in Germany]. Med Klin (Munich) 100: 193–199

    Article  Google Scholar 

  • Schouten BC, Meeuwesen L, Tromp F, Harmsen HA (2007) Cultural diversity in patient participation: the influence of patients’ characteristics and doctors’ communicative behaviour. Patient Educ Couns 67: 214–223

    Article  PubMed  Google Scholar 

  • Spiessl H, Schmid R, Cording C, Klein H, Adler L (2006) Die Bedeutung der Nutzerzufriedenheit für psychiatrische Kliniken. Krankenhauspsychiatrie 17: 2–8

    Article  Google Scholar 

  • Spiessl H, Leber C, Kaatz S, Cording C (2002) Was erwarten Patienten von einer psychiatrischen Abteilung an einem Allgemeinkrankenhaus? Psychiat Prax 29: 417–419

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inn-Salzach-Klinikum gGmbH Fachkrankenhaus für Psychiatrie, Psychotherapie, Psychosomatische Medizin und Neurologie, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Gabersee 7, 83512, Wasserburg am Inn, Deutschland

    Dr. rer.nat. Dipl.-Psych. Alexander Brunnauer

  2. Universitätsklinik für Psychiatrie, Auenbruggerplatz 31, 8036, Graz, Österreich

    Univ.-Prof. Dr. Dr. med. Hans-Peter Kapfhammer

  3. Centrum für Disease Management, Psychiatrische Klinik der Technischen Universität München, Möhlstrasse 26, 81675, München, Deutschland

    Dr. med. Werner Kissling

  4. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland

    PD Dr. med. Josef Bäuml

  5. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München, Möhlstraße 26, 81675, München, Deutschland

    Dr. med. Johannes Hamann

Authors
  1. Dr. rer.nat. Dipl.-Psych. Alexander Brunnauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Univ.-Prof. Dr. Dr. med. Hans-Peter Kapfhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. Werner Kissling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PD Dr. med. Josef Bäuml
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dr. med. Johannes Hamann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Klinische Neurochemie, Universität Würzburg, Deutschland

    Peter Franz Riederer

  2. Inn-Salzach-Klinikum gGmbH, Fachkrankenhaus für Psychiatrie, Psychotherapie, Psychosomatische Medizin und Neurologie, Wasserburg a. Inn · Rosenheim · Freilassing, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Deutschland

    Gerd Laux

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Brunnauer, A., Kapfhammer, HP., Kissling, W., Bäuml, J., Hamann, J. (2010). Psychologische Grundlagen. In: Riederer, P.F., Laux, G. (eds) Grundlagen der Neuro-Psychopharmakologie. Springer, Vienna. https://doi.org/10.1007/978-3-211-85473-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-85473-0_4

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-85472-3

  • Online ISBN: 978-3-211-85473-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation